Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial
المؤلفون المشاركون
Gao, Yue-Qiu
Zhang, Jing-Hao
Zheng, Chao
Zhang, Xin
Hou, Zhi-Jun
Wang, Yu-Qing
Wang, Kai-Xia
Yu, Zhuo
Li, Man
Zhou, Zheng-Hua
Sun, Xue-Hua
Zhu, Xiao-Jun
المصدر
Evidence-Based Complementary and Alternative Medicine
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-06-19
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Objective.
To ascertain the efficacy and safety of Ganji Formulation (GF) for patients with Hepatocellular carcinoma (HCC) who had undergone surgery.
Materials and Methods.
A total of 262 HCC patients who had undergone liver resection, local ablation, or transcatheter arterial chemoembolization (TACE) were divided randomly into the treatment group and control group.
The former was treated with GF and the later with placebo, both for 6 months.
The primary endpoint was overall survival (OS).
Second endpoints were disease-free survival (DFS) or time to disease progression (TTP).
Results.
OS of the treatment group was significantly longer than that of the control group (P < 0.05).
Subgroup analysis showed that, for patients who received TACE, the TTP was significantly longer in the treatment group than in the control group (P < 0.05).
However, for patients who underwent liver resection or local ablation, there was no significant difference in DFS between the two groups (P > 0.05).
Conclusion.
GF could improve postoperative cumulative survival and prolong the TTP.
This clinical trial number is registered with ChiCTR-IOR-15007349.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Zhang, Jing-Hao& Zheng, Chao& Zhu, Xiao-Jun& Zhang, Xin& Hou, Zhi-Jun& Zhou, Zheng-Hua…[et al.]. 2019. Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial. Evidence-Based Complementary and Alternative Medicine،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1151732
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Zhang, Jing-Hao…[et al.]. Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial. Evidence-Based Complementary and Alternative Medicine No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1151732
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Zhang, Jing-Hao& Zheng, Chao& Zhu, Xiao-Jun& Zhang, Xin& Hou, Zhi-Jun& Zhou, Zheng-Hua…[et al.]. Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial. Evidence-Based Complementary and Alternative Medicine. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1151732
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1151732
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر